A preliminary study to investigate effectiveness of a mixed extract of Dermatophagoides sp. house dust mites and Alternaria sp. MoldD. El-Qutob email@example.com, I. Raducan2, G. Mencia3Show more: Authors information and Publication history
Hospital Universitario de La Plana, Vila-real, Castellón, Spain2
Hospital Universitario Doctor Peset, Valencia, Spain3
Hospital Clínico Universitario de Valencia, Valencia, SpainHistory
Published: 09 September 2021
Accepted:15 December 2020
Received: 19 October 2020
10.23822/EurAnnACI.1764-1489.185Summary Background and objective
. Although the administration of single-allergen extractsis recommended, there are polysensitized patients who require a different strategy. This study evaluates the effectiveness of an extract containing a mixture of house dust mites (HDM) and mold allergens in polysensitized patients withasthma and/or rhinitis. Methods
. Using validated questionnaires, we assessed asthma and rhinitis control and quality of life (QOL) of patients that received a combined immunotherapy of HDM and mold in routine clinical practice. Results
. 39 polysensitized patients with asthma and/or rhinitis were included. After6 months of follow up, asthma control increased significantly from baseline and was maintained at 12 months. However, QOL of asthma patients did not changesignificantly from baseline to month 6 or 12, but at month 12, 57.9% of them improved their score and 5.3% maintained the same. On the other hand, QOL of 76.9% patients with rhinitis improved significantly at both 6 and 12 months. Conclusions
. In this preliminary study, the administration of immunotherapy based on the combination of allergens from HDM and mold, besides being effective, also allows an increase in the quality of life of patients with asthma and/or rhinitis. Key words
Real-world evidence; subcutaneous immunotherapy; house dust mites; Dermatophagoides
; quality of life.
Cite this article as:
El-Qutob D, Raducan I, Mencia G. Which skin prick test wheal size detects true allergy toSalsola kali? Eur Ann Allergy Clin Immunol 2021;53(5):234-239. doi: 10.23822/EurAnnACI.1764-1489.185.